Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection

Br J Dermatol. 2018 Nov;179(5):1179-1180. doi: 10.1111/bjd.16799. Epub 2018 Jul 26.

Authors

F Brunet-Possenti^{1

2}, C Charpentier², G Collin², D Descamps², V Descamps¹

Affiliations

¹ Department of Dermatology, Bichat Claude Bernard Hospital, AP-HP, Paris, France.
² IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France.

PMID: 29777619
DOI: 10.1111/bjd.16799

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Humanized
Carrier State / drug therapy*
Female
Foreskin / virology
Humans
Injections, Subcutaneous
Interleukin-17 / antagonists & inhibitors
Male
Middle Aged
Papillomaviridae / isolation & purification*
Skin / virology
Treatment Outcome
Vagina / virology
Warts / drug therapy*
Warts / virology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
IL17A protein, human
Interleukin-17
secukinumab